دورية أكاديمية

Circulating DNA microsatellites: molecular determinants of response to biochemotherapy in patients with metastatic melanoma.

التفاصيل البيبلوغرافية
العنوان: Circulating DNA microsatellites: molecular determinants of response to biochemotherapy in patients with metastatic melanoma.
المؤلفون: Taback, Bret, O'Day, Steven J., Boasberg, Peter D., Shu, Sherry, Fournier, Patricia, Elashoff, Robert, He-Jing Wang, Hoon, Dave S.B., Wang, He-Jing
المصدر: JNCI: Journal of the National Cancer Institute; 1/21/2004, Vol. 96 Issue 2, p152-156, 5p, 1 Chart, 2 Graphs
مصطلحات موضوعية: DRUG therapy, MELANOMA, MICROSATELLITE repeats, MEDICAL genetics, PROGNOSIS, CANCER treatment
مستخلص: Although biochemotherapy appears to be a promising treatment for metastatic melanoma, its impact remains unpredictable. Microsatellite markers for loss of heterozygosity (LOH) appear to have prognostic significance when identified in primary tumors and serum and/or plasma from cancer patients. However, their association with response to systemic therapy has yet to be assessed. To determine whether microsatellite markers are associated with response to therapy, serum from 41 patients with metastatic melanoma, drawn before the initiation of biochemotherapy, was analyzed for LOH with nine microsatellite markers. During a median follow-up of 13 months, the overall response rate for these 41 patients was 56%, including 13 (32%) complete responses and 10 (24%) partial responses. LOH was detected in sera from 12 (29%) of the 41 patients. The response rate of these 12 patients was 17% (95% confidence interval [CI] = 5% to 45%), whereas that of the 29 patients without LOH was 72% (95% CI = 54% to 85%) (P =.001). All statistical tests were two-sided. The presence of LOH was statistically significant and independently associated with disease progression (multivariable analysis, P =.003). Circulating tumor DNA markers may be useful in assessing prognosis for advanced melanoma patients and their response to biochemotherapy. [ABSTRACT FROM AUTHOR]
Copyright of JNCI: Journal of the National Cancer Institute is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:00278874
DOI:10.1093/jnci/djh011